LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix Inc., a biotechnology company discovering and developing a broad new class of therapies for the treatment, prevention and transmission control of respiratory diseases, announced today it will initiate a randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial of its novel inhaled therapy, PUR003, to demonstrate its effectiveness, safety and tolerability in an experimental influenza challenge study. The study will begin in the third quarter of 2009.
